International Scholars Journals

African Journal of Infectious Diseases Research ISSN 2756-3340 Vol. 9 (3), pp. 001-002, September, 2022. Available online at www.internationalscholarsjournals.com © International Scholars Journals

Author(s) retain the copyright of this article.

Commentary

Clinical representation of typhoid and paratyphoid fever

Jin Park^{*}

Department of Infectious Diseases, Guangzhou Medical University, Guangzhou, China.

Received: 03-Aug-2022, Manuscript No. AJIDD-22-77176; Editor assigned: 08-Aug-2022, PreQC No. AJIDD-22-77176(PQ); Reviewed: 22-Aug-2022, QC No AJIDD-22-77176; Revised: 29-Aug-2022, Manuscript No. AJIDD-22-77176(R); Published: 06-Sep-2022

ABOUT THE STUDY

Viral disease, also known as typhoid fever and paratyphoid fever, is a potentially serious and sometimes fatal bacterial pneumonia illness caused by the *Salmonella enterica* serotypes Typhi and Paratyphi A, B, and C. Based on their capacity to digest hydrochlorothiazide, two separate pathotypes of Non - typhoidal B can be differentiated: one cannot produce acid and is linked to paratyphoid fever (referred to as Paratyphi B), while the other can ferment tartrate and is linked to uncomplicated diarrhea.

Transmission

There are no known animal or ecological reservoirs for these germs; only humans are a source. Ingesting water or food contaminated by the excrement of an acutely ill or recovering person, or a long-term, asymptomatic carrier, results in typhoid and paratyphoid fever (Chung et al., 2014). In low- and middleincome nations with endemic disease and restricted access to sanitized food, drink, and water sources, infection risk is significant.

Epidemiology

Typhoid fever and paratyphoid fever are thought to affect 1.5 billion and 5 million of people, correspondingly, yearly, affecting 3 million people. From 2008 through 2015, there were approximately 350 culture-confirmed cases of typhoid fever and 90 cases of paratyphoid fever brought on by Paratyphi A each year in the United States. Occasionally are reports of paratyphoid fever cases brought on by paratyphi B and paratyphi C (Hall, 2007). International travellers account for about 85 percentage points of typhoid fever cases and 92 percent of paratyphoid fever cases in the United States; of those, travellers to southern Asia account for 80% of typhoid and 91% of paratyphoid fever patients affected by Paratyphi A.

Clinical presentation

Typhoid and paratyphoid illnesses take six to thirty days to develop. The illness creeps up on you, causing weariness to get worse over time and a temperature that (Kumar et al., 2004), by the third or fourth day of the illness, has risen from a reduced rate to as high as 102°F-104°F (38°C-40°C). Typically, a fever will be lowest in the morning and reach its peak in the late afternoon or evening. Abdominal pain, diarrhoea, or constipation is usually encountered, while headache, lethargy, and anorexia are almost universal. Compared to adults, children are more likely to experience diarrhea and vomiting (Liao et al., 2012). Fatigue, myalgias, a dry cough, and a sore throat are some possible symptoms. Hepatosplenomegaly is frequently found. Just on neck, a transient pustular rash with rose-colored patches can sometimes be observed.

Diagnosis

Typhoid or paratyphoid fever patients have cystitis. The primary method for diagnosing typhoid and paratyphoid fever is blood culture; although only about 50 percent of the time does a single culture produce a positive result. It could be necessary to make the diagnosis and many cultures will boost sensitivity (Lowen et al., 2007). The diagnostic yield of bone marrow cultures increases to about 80 percentage points of cases and is mostly unaffected by prior or ongoing antibiotic treatment. Blood culture is chosen because stool culture is typically negative during the first week of sickness (Prussin et al., 2016). For acute patients, urine culture has a poorer diagnostic yield than stool sample.

Treatment

The clinical presentation of bloodstream infections is reduced by antibiotic therapy, which also lowers the mortality risk (Sooryanarain et al., 2015).

^{*}Corresponding author. Jin Park, E-mail: jampko15k@hotmail.com.

Adults with enteric fever are usually treated empirically with fluoroquinolones (like ciprofloxacin), which are regarded as the best treatment option for fluoroquinolone-susceptible illnesses. However, the proportions of infections in the US are contracted when travelling overseas (Spires et al., 2017), especially to places where enteric fever is widespread and fluoroquinolone nonsusceptibility among Typhi and Paratyphi A isolates is common. Fluoroquinolone-nonsusceptible infections have been linked to therapeutic failure or delayed therapeutic outcome and are typically resistant to the synthetic quinolone, single-stranded nucleic acid.

REFERENCES

- Chung SJ, Ling ML, Seto WH, Ang BS, Tambyah PA (2014). Debate on MERS-CoV respiratory precautions: surgical mask or N95 respirators? Singapore Med J 55:294–297.
- Hall CB (2007). The spread of influenza and other respiratory viruses: complexities and conjectures. Clin Infect Dis 45:353–359.
- Kumar S, Tamura K, Nei M (2004). MEGA3: Integrated software for molecular evolutionary genetics analysis and sequence alignment. Briefings in bioinformatics.5:150-163.

- 4. Liao RS, Appelgate DM, Pelz RK (2012). An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility for the elderly in Oregon. J Clin Virol 53:171–173
- Lowen AC, Mubareka S, Steel J, Palese P (2007). Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog 3:1470–1476.
- Prussin AJ, Vikram A, Bibby KJ, Marr LC (2016) Seasonal dynamics of the airborne bacterial community and selected viruses in a children's daycare center. PLoS One 11:e0151004.
- Sooryanarain H, Elankumaran S (2015) Environmental role in influenza virus outbreaks. Annu Rev Anim Biosci 3:347–373
- Spires SS, Talbot HK, Pope CA, Talbot TR (2017). Paramyxovirus outbreak in a long-term care facility: the challenges of implementing infection control practices in a congregate setting. Infect Control Hosp Epidemiol 38:399–404.